Zdrowie i gospodarka · 11/09/2024
FDA Classifies Whole Exome Sequencing Constituent Device into Class II with Special Controls
The FDA has classified the whole exome sequencing constituent device into Class II with special controls, aiming to ensure its safety and effectiveness while enhancing patients' access to innovative devices.
Source: Federal Register — Food and Drug AdministrationOpen original release →